Journal article

Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections

Shihui Yu, Shaoning Wang, Peizhi Zou, Guihong Chai, Yu-Wei Lin, Tony Velkov, Jian Li, Weisan Pan, Qi Tony Zhou

International Journal of Pharmaceutics | ELSEVIER | Published : 2020

Abstract

The aim of this study was to design and characterize dry powder inhaler formulations of ciprofloxacin and colistin co-loaded liposomes prepared by the ultrasonic spray-freeze-drying (USFD) technique. Liposomal formulations and powder production parameters were optimized to achieve optimal characteristics and in-vitro performance such as encapsulation efficiency (EE), particle size, particle distribution index (PDI), fine particle fraction (FPF), emitted dose (ED) and in vitro antibacterial activity. The formulation (F6) with the mannitol (5% w/v) as the internal lyoprotectant and sucrose (5%, w/v), mannitol (10%, w/v) and leucine (5%, w/w) as the external lyoprotectants/aerosolization enhanc..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Institute of Allergy and Infectious Diseases of the National Institute of Health


Awarded by National Institute of Allergy and Infectious Diseases of the National Institutes of Health


Funding Acknowledgements

Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institute of Health under Award Number R01AI146160. Qi Tony Zhou and Jian Li are also supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R01AI132681. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health. The authors are thankful for the cryo-TEM imaging by Valorie D. Bowman at Purdue Cryo Electron Microscopy Facility.